Efpeglenatide

Fat Loss Augmentation + Lean Mass Increase Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass Increase Improved Weight Loss and Muscle Preservation with HM15275 Combination Therapy SEOUL, South Korea, Nov. 6, 2024 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean muscle mass, marking it as a potential game-changer in obesity management. HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug developed combining advanced artificial intelligence and structural modeling technology with Hanmi's innovative R&D expertise," said Dr. In Young Choi, Head of Hanmi's R&D Center. "It selectively reduces fat while increasing muscle, establishing a new paradigm for high quality obesity treatment. The drug shows significant promise as both monotherapy and combination therapy to improve weight loss potency and quality," he added. As a peptide-based therapy, HM17321 is anticipated to provide a more cost-effective alternative to antibody-based muscle-preserving drugs, such as myostatin-targeting monoclonal antibodies (mAbs), while also demonstrating enhanced compatibility with incretin-based obesity treatments. Hanmi unveiled its latest findings at 2024 ObesityWeek, an annual obesity-focused conference held in San Antonio, Texas, from November 3 to 6. Hanmi presented two preclinical studies in poster format, underscoring HM17321's double-action(fat loss and lean muscle gain) benefits and a development strategy that highlights both quantitative and qualitative improvements in weight loss. Unlike conventional incretin-based drugs, HM17321 targets the CRF2 (Corticotropin-Releasing Factor 2) receptor to selectively reduce fat while enhancing muscle mass. This unique approach sets it apart from existing therapies. Current GLP-1-based obesity medications are effective in achieving 15-20% weight loss, but up to 40% of this loss can come from muscle, accompanied by a reduction in basal metabolic rate and a high risk of rapid weight regain (the "yo-yo" effect) after discontinuation. Hanmi reported at the conference that, in animal models, HM17321 achieved weight loss levels comparable to semaglutide, a prominent GLP-1-based therapy, but with the added benefit of increased lean body and muscle mass. This capability makes HM17321 a first-in-class drug, providing a differentiated strategy to high quality weight management by focusing on both fat loss and muscle enhancement simultaneously. In addition to HM17321, Hanmi presented a separate study on the combined use of HM17321 with HM15275, a next-generation anti-obesity drug (LA-GLP/GIP/GCG), and semaglutide. The combination therapy demonstrated a substantial reduction in body weight and fat mass compared to monotherapies, effectively preventing the muscle loss that accompanies significant weight loss treatments. These findings underscore HM17321's role in improving the quality of weight loss by reducing fat, increasing muscle mass, and enhancing muscle function, making it advantageous in both monotherapy and combination therapies. Hanmi also presented follow-up nonclinical data on HM15275(LA-GLP-1/GIP/GCG), previously unveiled at the American Diabetes Association (ADA) conference. This novel anti-obesity candidate not only demonstrates potential for over 25% weight loss with minimal muscle loss but also offers therapeutic benefits for metabolic diseases. At 2024 ObesityWeek, Hanmi highlighted HM15275's mechanism of action, which facilitates favorable metabolic phenotype change and enhances energy metabolism alongside dietary control. These effects clearly highlight how HM15275 could distinguish itself from current incretin-based obesity drugs, which primarily rely on appetite suppression. HM15275 is currently in Phase 1 clinical trials in the United States, with plans to progress to Phase 2 trials by 2025, positioning it as a 'best-in-class' candidate in obesity treatment. Reflecting on these innovative R&D achievements, Dr. Choi stated, "This year, Hanmi has fortified its leadership in obesity treatment through the unveiling of HM17321 and HM15275. These innovations continue the momentum started by efpeglenatide within our H.O.P project. Our commitment to pioneering R&D will drive unprecedented advancements in obesity treatment, addressing challenges once thought insurmountable." Official Website: SOURCE Hanmi Pharmaceutical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research. Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research. The move comes as Sanofi’s diabetes and cardiovascular business has struggled for several years. According to the company’s most recent financial reports, the diabetes business accounted for about 13% of its revenue stream, down nearly 10% from the previous year. New Sanofi Chief Executive Officer Paul Hudson will formally outline his strategic thinking to investors today, according to Bloomberg . The announcement comes one day after Sanofi acquired San Diego-based Synthorx for $2.5 billion. The acquisition brings Synthorx’s lead immuno-oncology candidate THOR-707, an interleukin-2 form being developed as a potential treatment for solid tumors into Sanofi’s pipeline. For Sanofi, the Synthorx acquisition was the first big multi-billion-dollar move the company has made since January of last year when it acquired Biogen spinout Bioverativ for about $11.6 billion. That move provided Sanofi with a significant presence in the hemophilia market. On a Monday conference call with reporters, Hudson pointed to six primary focuses for Sanofi as it undergoes its transformation. Those areas of focus include hemophilia, oncology, hematology, rare diseases and neurology. The acquisition of Synthorx is one of the first steps the company is making toward that transformation under Hudson’s guidance. In those core areas, the company already has investigational therapies that could provide treatment in areas of high unmet patient need. Among those assets are the RNAi treatment fitusiran for hemophilia, a selective estrogen receptor degrader for hormone-receptor-positive breast cancer and multiple sclerosis candidate BTKi, which the company believes has the potential to be the first disease-modifying therapy to address inflammation and disability drivers in the brain. hbspt.cta.load(4413123, '4e87abe9-779b-4c65-98dd-ea451779faa9', {}); Sanofi also sees future growth from its partnership with Regeneron and the blockbuster drug Dupixent. Sanofi said it expects strong growth and more than $11 billion in peak sales. Vaccines are another growth area. The company said new launches, including its newly-approved Dengue fever treatment , will provide pathways of growth. On Monday, the company’s vaccines business snagged $226 million in grant money from the Department of Health and Human Services to increase the company’s domestic pandemic influenza vaccine production capabilities in Pennsylvania. But, as the company focuses on high-growth areas like cancer that means it is walking away from a decades-long history of developing drugs for diabetes and heart disease. While the insulin product Lantus will remain on the market, Hudson noted that Sanofi will not look to launch efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, it acquired in a 2015 $4.2 billion licensing deal with South Korea’s Hanmi Pharmaceuticals. The company will look to unload the experimental treatment to another developer, Bloomberg reported. In a statement ahead of today’s Capital Markets Day, Hudson said the company’s new strategy will position the company to “achieve breakthroughs” with its most promising medicines. He said the company will anchor its efforts in “leading-edge science” and will have a focus on delivering results. “Sanofi gained leadership and changed the practice of medicine in diabetes and cardiovascular diseases. We are now preparing for our next cycle, with a new round of innovative solutions for patients. I’m confident we will achieve long-term growth and value for shareholders while turning innovation into transformative medicines for patients,” Hudson said in a statement. Additionally, the company will also spin off its consumer healthcare business into a standalone operation. “Our objective for the Consumer Healthcare business is to unlock value and entrepreneurial energy by growing faster than the market over the mid-term. We believe the new standalone structure, coupled with plans to accelerate the over-the-counter switches for Cialis and Tamiflu, will position the business well to accomplish this ambition,” Hudson said.